IC
BCRX icon

IEQ Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History

IEQ Capital’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-71,950
Closed -$546K – 1867
2025
Q3 		$546K Sell
71,950
-52,433
-42% -$437K ﹤0.01% 1251
2025
Q2 		$1.11M Buy
124,383
+1,680
+1% +$15.6K 0.01% 822
2025
Q1 		$920K Buy
122,703
+93,267
+317% +$752K 0.01% 783
2024
Q4 		$221K Buy
+29,436
New +$223K ﹤0.01% 1162

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

IEQ Capital's BCRX Position: Q4 2025 in Review

IEQ Capital sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2025, closing a stake of 71,950 shares — an estimated $546K sold.

IEQ Capital first reported a position in BCRX in Q4 2024 and held it in 4 quarters. The position peaked at $1.11M in Q2 2025. 273 funds tracked by Wall St. Rank hold BCRX as of Q4 2025.

  • IEQ Capital reported no remaining BioCryst Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • IEQ Capital sold 71,950 BioCryst Pharmaceuticals shares in Q4 2025, an estimated $546K.
  • IEQ Capital first reported a position in BioCryst Pharmaceuticals in Q4 2024 and held it in 4 quarters.
  • IEQ Capital's BioCryst Pharmaceuticals position peaked at $1.11M in Q2 2025.
  • 273 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2025.

Based on IEQ Capital's 13F filing for Q4 2025, filed 13 Feb 2026.